サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1606456

2型糖尿病市場：薬剤クラス別、投与経路別、流通チャネル別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2024年～2032年

Type 2 Diabetes Market, By Drug Class, By Route of Administration, By Distribution Channel, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 288 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
2型糖尿病市場：薬剤クラス別、投与経路別、流通チャネル別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2024年～2032年
出版日: 2024年11月04日
発行: AnalystView Market Insights
ページ情報: 英文 288 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

2型糖尿病市場規模は2023年に348億4,909万米ドルとなり、2024年から2032年にかけてCAGR 8.40％で拡大

2型糖尿病市場-市場力学

世界の2型糖尿病罹患率の増加が市場需要を促進

世界中で2型糖尿病の罹患率が上昇しているのは、主にライフスタイルの変化と人口の高齢化が原因であり、これが2型糖尿病市場の成長を促進する主な要因となっています。世界保健機関（WHO）によると、糖尿病患者の95％以上が2型糖尿病です。また、世界の肥満や過体重の増加は、2型糖尿病の罹患率の上昇と密接な関係があり、過剰な体重はインスリン抵抗性を著しく増加させるからです。しかし、糖尿病治療機器は高価であり、医薬品の進歩にもかかわらず、多くの患者が新しい糖尿病治療薬の存在を知らないため、糖尿病治療機器の普及が制限され、市場の成長が鈍化しています。それとは逆に、グルカゴン様ペプチド-1受容体作動薬（Tanzeum、Trulicity）やナトリウムグルコース共輸送体-2阻害薬（Jardiance）などの医薬品開発は、2型糖尿病市場に大きな成長機会をもたらすと予測されています。

2型糖尿病市場-主要インサイト

当社のリサーチアナリストが共有した分析によると、世界市場は予測期間（2024-2032年）に約8.40%のCAGRで毎年成長すると予測されています。

薬剤クラス別では、ナトリウムグルコース共輸送体2（SGLT2）阻害薬が2023年に最大市場シェアを示すと予測されました。

投与経路別では、経口剤が2023年に主要セグメントとなった。

エンドユーザー別では、2023年には在宅介護が主要セグメントでした。

地域別では、北米の2型糖尿病市場が2023年に主要な収益源となった

2型糖尿病市場-セグメンテーション分析：

世界の2型糖尿病市場は、薬剤クラス別、投与経路別、流通チャネル別、エンドユーザー別、地域別に区分されます。

薬剤クラス別では、ジペプチジルペプチダーゼ4阻害薬、ナトリウムグルコース共輸送体2（SGLT2）阻害薬、グルカゴン様ペプチド1受容体作動薬、その他の4つに分類されます。市場を独占しているのはナトリウム・グルコース共輸送体2（SGLT2）阻害薬です。これは主に、血糖値を下げ、心血管イベントや腎イベントのリスクを低減する効果によるものです。

市場は流通チャネル別では、オンライン薬局、小売薬局、病院薬局の3つに分類されます。予測期間中、オンライン部門が最も高いCAGRで上昇すると予測されます。これは主に、糖尿病治療薬への便利なアクセスに対する需要の高まりにより、患者が自宅から簡単に処方箋を注文できるようになり、多くの患者にとって好ましい選択肢となっているためです。

2型糖尿病市場-地理的洞察

地理的に、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東アフリカの各地域に広がっています。これらの地域は、ビジネスをもたらす国によってさらに分けられます。

2型糖尿病市場-競合情勢：

世界の2型糖尿病市場は、この疾患の有病率の増加と効果的な管理オプションに対する需要の高まりによって急速に成長しています。同市場の競合情勢は、eコマースや小売店との提携など様々な流通チャネルを活用する国内外のプレーヤーによって構成されています。各社は競争力のある価格設定、製品の品質、技術革新によって差別化を図っています。市場シェアを拡大するための主な戦略には、新製品の発売、研究開発への投資、M&Aの推進などがあり、これらはすべて、効果的な糖尿病治療を求める患者の進化するニーズに応えることを目的としています。

目次

第1章 2型糖尿病市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 2型糖尿病の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 2型糖尿病産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 2型糖尿病市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 2型糖尿病市場情勢

  • 2型糖尿病市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 2型糖尿病市場-薬剤クラス別

  • 概要
    • 薬剤クラス別：セグメントシェア分析
    • ジペプチジルペプチダーゼ-4阻害剤
    • ナトリウム-グルコース共輸送体（SGLT2）阻害剤
    • グルカゴン様ペプチド1受容体作動薬
    • その他

第8章 2型糖尿病市場- 投与経路別

  • 概要
    • 投与経路別：セグメントシェア分析
    • 非経口
    • 経口

第9章 2型糖尿病市場- 流通チャネル別

  • 概要
    • 流通チャネル別：セグメントシェア分析
    • オンライン薬局
    • 小売薬局
    • 病院薬局

第10章 2型糖尿病市場- エンドユーザー別

  • 概要
    • エンドユーザー別：セグメントシェア分析
    • 病院・クリニック
    • ホームケア設定
    • 学術調査機関
    • その他

第11章 2型糖尿病市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋地域
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析-2型糖尿病業界

  • 競合ダッシュボード
    • Competitive Benchmarking
    • Competitive Positioning
  • 企業プロファイル
    • Eli Lilly and Company
    • Sanofi
    • Merck &Co., Inc.
    • AstraZeneca PLC
    • Boehringer Ingelheim
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Novartis AG
    • Roche Holding AG
    • Daiichi Sankyo Company, Limited
    • Sun Pharmaceutical Industries Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Aurobindo Pharma Limited
    • Lupin Limited
    • Medtronic
    • B. Braun Melsungen AG
    • F. Hoffmann-La Roche
    • Abbott Laboratories
    • Insulet Corporation
    • Torrent Pharmaceuticals Limited
    • Takeda Pharmaceuticals Limited
    • Acon Laboratories, Inc.
    • Akros Pharma
    • Adocia
    • Amgen
    • Bayer AG
    • Biocon
    • Becton, Dickson, and Company
    • Peptron
    • Others

第13章 アナリストの全方位展望

目次
Product Code: ANV4171

REPORT HIGHLIGHT

Type 2 diabetes market size was valued at USD 34,849.09 Million in 2023, expanding at a CAGR of 8.40% from 2024 to 2032.

Type 2 diabetes is a chronic metabolic disorder where the body either resists insulin or doesn't produce enough of it, leading to high blood sugar levels. Symptoms may be mild or unnoticed for years, with signs like increased thirst, frequent urination, fatigue, or tingling in the hands and feet. Diagnosis typically involves blood tests like fasting plasma glucose or the A1C test to assess average blood sugar levels.

Type 2 Diabetes Market- Market Dynamics

Increasing prevalence of type 2 diabetes across the globe to propel market demand

The rising incidence of type 2 diabetes among people worldwide is mainly due to the lifestyle changes and aging populations is the major factor driving the growth of the type 2 diabetes market. According to the World Health Organization (WHO), more than 95% of people with diabetes have type 2 diabetes. Besides, the global rise in obesity and overweight individuals is closely linked to higher rates of type 2 diabetes, as excess weight significantly increases insulin resistance. However high cost of devices and despite pharmaceutical advancements, many patients are unaware of novel diabetes drugs, limiting their adoption and slowing market growth. On the contrary, pharmaceutical developments, such as glucagon-like peptide-1 receptor agonists (Tanzeum, Trulicity) and sodium glucose cotransporter-2 inhibitors (Jardiance) are predicted to create massive growth opportunities for the type 2 diabetes market.

Type 2 Diabetes Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.40% over the forecast period (2024-2032)

Based on drug class segmentation, sodium-glucose cotransporter 2 (SGLT2) inhibitors was predicted to show maximum market share in the year 2023

Based on route of administration segmentation, oral was the leading segment in 2023

Based on end-user segmentation, homecare was the leading segment in 2023

On the basis of region, the North America type 2 diabetes market was the leading revenue generator in 2023

Type 2 Diabetes Market- Segmentation Analysis:

The Global Type 2 Diabetes Market is segmented on the basis of Drug Class, Route of Administration, Distribution Channel, End User, and Region.

The market is divided into four categories based on drug class: dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 receptor agonists, and others. The sodium-glucose cotransporter 2 (SGLT2) sector dominates the market. This is majorly owing to their effectiveness in lowering blood sugar and reducing the risk of cardiovascular and renal events.

The market is divided into three categories based on distribution channel: online pharmacies, retail pharmacies, and hospital pharmacies. The online sector is predicted to rise at the highest CAGR during the forecast period. This is mainly because the increasing demand for convenient access to diabetes medications allows patients to order prescriptions easily from home, making it a preferred option for many.

Type 2 Diabetes Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Type 2 Diabetes Market- Competitive Landscape:

The global type 2 diabetes market is rapidly growing, driven by the increasing prevalence of the disease and rising demand for effective management options. This market features a competitive landscape comprised of both international and local players who utilize various distribution channels, including e-commerce and retail partnerships. Companies differentiate themselves through competitive pricing, product quality, and innovation. Key strategies for expanding market share include launching new products, investing in research and development, and pursuing mergers and acquisitions, all aimed at meeting the evolving needs of patients seeking effective diabetes care.

Recent Developments:

In October 2023, Glenmark Pharmaceuticals announced the launch of India's first triple-drug fixed-dose combination (FDC) therapy for adults with Type 2 diabetes and comorbidities. Named Zita DM, the drug combines three medications to enhance glycemic control, helping patients maintain optimal blood glucose levels. This marks a significant innovation in diabetes management in India.

In June 2024, the FDA approved AstraZeneca's Farxiga (dapagliflozin) to help control blood sugar levels in children aged 10 and up with type 2 diabetes. This approval is based on encouraging findings from the T2NOW Phase III trial. Farxiga was previously authorized for adults, supporting blood sugar management alongside diet and exercise.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL TYPE 2 DIABETES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Novo Nordisk
  • Eli Lilly and Company
  • Sanofi
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Novartis AG
  • Roche Holding AG
  • Daiichi Sankyo Company, Limited
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Aurobindo Pharma Limited
  • Lupin Limited
  • Medtronic
  • B. Braun Melsungen AG
  • F. Hoffmann-La Roche
  • Abbott Laboratories
  • Insulet Corporation
  • Torrent Pharmaceuticals Limited
  • Takeda Pharmaceuticals Limited
  • Acon Laboratories, Inc.
  • Akros Pharma
  • Adocia
  • Amgen
  • Bayer AG
  • Biocon
  • Becton, Dickson, and Company
  • Peptron
  • Others

GLOBAL TYPE 2 DIABETES MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Dipeptidyl Peptidase-4 Inhibitors
  • Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
  • Glucagon-like Peptide 1 Receptor Agonists
  • Others

GLOBAL TYPE 2 DIABETES MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Parenteral
  • Oral

GLOBAL TYPE 2 DIABETES MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Online Pharmacies
  • Retail Pharmacies
  • Hospital Pharmacies

GLOBAL TYPE 2 DIABETES MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals & Clinics
  • Homecare Settings
  • Academic & Research Institutes
  • Others

GLOBAL TYPE 2 DIABETES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Type 2 Diabetes Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Type 2 Diabetes Market Snippet by Drug Class
    • 2.1.2. Type 2 Diabetes Market Snippet by Route of Administration
    • 2.1.3. Type 2 Diabetes Market Snippet by Distribution Channel
    • 2.1.4. Type 2 Diabetes Market Snippet by End User
    • 2.1.5. Type 2 Diabetes Market Snippet by Country
    • 2.1.6. Type 2 Diabetes Market Snippet by Region
  • 2.2. Competitive Insights

3. Type 2 Diabetes Key Market Trends

  • 3.1. Type 2 Diabetes Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Type 2 Diabetes Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Type 2 Diabetes Market Opportunities
  • 3.4. Type 2 Diabetes Market Future Trends

4. Type 2 Diabetes Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Type 2 Diabetes Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Type 2 Diabetes Market Landscape

  • 6.1. Type 2 Diabetes Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Type 2 Diabetes Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. Dipeptidyl Peptidase-4 Inhibitors
    • 7.1.3. Sodium-glucose Cotransporter (SGLT2) Inhibitors
    • 7.1.4. Glucagon-like Peptide 1 Receptor Agonists
    • 7.1.5. Others

8. Type 2 Diabetes Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Parenteral
    • 8.1.3. Oral

9. Type 2 Diabetes Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 9.1.2. Online Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Hospital Pharmacies

10. Type 2 Diabetes Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
    • 10.1.2. Hospitals & Clinics
    • 10.1.3. Homecare Settings
    • 10.1.4. Academic & Research Institutes
    • 10.1.5. Others

11. Type 2 Diabetes Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Type 2 Diabetes Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Type 2 Diabetes Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Type 2 Diabetes Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Type 2 Diabetes Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Type 2 Diabetes Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Type 2 Diabetes Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Eli Lilly and Company
    • 12.2.2. Sanofi
    • 12.2.3. Merck & Co., Inc.
    • 12.2.4. AstraZeneca PLC
    • 12.2.5. Boehringer Ingelheim
    • 12.2.6. GlaxoSmithKline plc
    • 12.2.7. Pfizer Inc.
    • 12.2.8. Novartis AG
    • 12.2.9. Roche Holding AG
    • 12.2.10. Daiichi Sankyo Company, Limited
    • 12.2.11. Sun Pharmaceutical Industries Ltd.
    • 12.2.12. Dr. Reddy's Laboratories Ltd.
    • 12.2.13. Aurobindo Pharma Limited
    • 12.2.14. Lupin Limited
    • 12.2.15. Medtronic
    • 12.2.16. B. Braun Melsungen AG
    • 12.2.17. F. Hoffmann-La Roche
    • 12.2.18. Abbott Laboratories
    • 12.2.19. Insulet Corporation
    • 12.2.20. Torrent Pharmaceuticals Limited
    • 12.2.21. Takeda Pharmaceuticals Limited
    • 12.2.22. Acon Laboratories, Inc.
    • 12.2.23. Akros Pharma
    • 12.2.24. Adocia
    • 12.2.25. Amgen
    • 12.2.26. Bayer AG
    • 12.2.27. Biocon
    • 12.2.28. Becton, Dickson, and Company
    • 12.2.29. Peptron
    • 12.2.30. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us